PLX4720

PLX4720

CAT N°: 15142
Price:

From 66.00 56.10

The Raf kinases activate cellular pathways that lead to cell proliferation and can contribute to certain types of cancer.{19941,24815} Mutations in the kinase B-Raf are involved in a wide range of cancers.{18549,22622} In particular, the mutation B-RafV600E occurs in melanomas and thyroid cancer but is poorly targeted by many inhibitors of wild type B-Raf.{24813,24814} PLX4720 is an orally-available, highly selective inhibitor of B-RafV600E (IC50 = 13 nM).{24814} It is less effective against wild type B-Raf (IC50 = 160 nM) as well as several other kinases.{24814} PLX4720 induces cell cycle arrest and apoptosis in cells and xenografts expressing the mutant of B-Raf.{24813,24814,24812}

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View